---
title: "Hybio Pharmaceutical Co.,Ltd. (300199.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300199.SZ.md"
symbol: "300199.SZ"
name: "Hybio Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T15:22:29.771Z"
locales:
  - [en](https://longbridge.com/en/quote/300199.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300199.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300199.SZ.md)
---

# Hybio Pharmaceutical Co.,Ltd. (300199.SZ)

## Company Overview

Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermediates for endocrine, nutritional, and metabolic diseases; digestive system diseases; neoplasms; nervous system diseases; pregnancy, childbirth, and puerperium; musculoskeletal system and connective tissue diseases; infectious and parasitic diseases; circulatory system diseases; blood and hematopoietic organ diseases; and genitourinary system diseases, as well as factors influencing health status. It also provides contract research, development, and manufacturing organization (CRDMO) services for peptide APIs, peptide formulations, oligonucleotide drugs, and pharmaceutical intermediates.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.hybio.com.cn](https://www.hybio.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.41)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 80 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 27.42% |  |
| Net Profit YoY | 205.39% |  |
| P/B Ratio | 28.49 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 21164711704.65 |  |
| Revenue | 957227639.99 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 13.60% | B |
| Profit Margin | 9.89% | B |
| Gross Margin | 64.90% | A |
| Revenue YoY | 27.42% | A |
| Net Profit YoY | 205.39% | A |
| Total Assets YoY | 10.85% | B |
| Net Assets YoY | 13.61% | B |
| Cash Flow Margin | 279.22% | A |
| OCF YoY | 27.42% | A |
| Turnover | 0.30 | D |
| Gearing Ratio | 77.52% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hybio Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "27.42%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "205.39%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "28.49",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "21164711704.65",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "957227639.99",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "13.60%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "9.89%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "64.90%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "27.42%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "205.39%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "10.85%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "13.61%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "279.22%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "27.42%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.30",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "77.52%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 219.61 | 157/215 | 218.30 | 196.06 | 193.81 |
| PB | 27.99 | 217/215 | 28.60 | 25.76 | 24.44 |
| PS (TTM) | 21.72 | 211/215 | 22.14 | 19.74 | 18.04 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300199.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300199.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300199.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300199.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**